Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Combination Trial of Copaxone Plus Estriol in RRMS

Trial Profile

A Combination Trial of Copaxone Plus Estriol in RRMS

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Estriol succinate (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Estriol in MS
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Feb 2016 According to a Synthetic Biologics media release, on the basis of findings from an independent third party analysis, the Company has decided to terminate its license and clinical trial agreements relating to Trimesta with the Regents of the University of California.
    • 02 Feb 2016 Primary endpoint [Relapse rate (At 2 years)] has not been met, according to a Synthetic Biologics media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top